Quantum Genesis AI Corp. (Quantumzyme Corp.) Files Amendment to Q3 2025 10-Q/A: Key Updates for Investors

Summary of Key Points

• Company Name: Quantum Genesis AI Corp. (formerly Quantumzyme Corp.)
• Reporting Period: Quarter ended October 31, 2025
• Amendment Focus: Disclosure regarding intellectual property and formalization of rights previously acquired
• No Revenue Generated: The company reported zero revenues for Q3 2025 and Q3 2024
• Net Loss: Q3 2025 net loss was \$49,868 (improved from \$65,523 in Q3 2024)
• Operating Expenses: \$39,196 in Q3 2025, down from \$60,934 in Q3 2024
• Liquidity: Working capital deficit stands at \$490,585
• Going Concern: Substantial doubt regarding the company’s ability to continue as a going concern
• Intellectual Property: Patent application filed for proprietary enzyme technology; formal assignment agreement executed
• Share Count: 38,962,050 shares of common stock outstanding as of December 15, 2025

Detailed Article

Quantum Genesis AI Corp. (formerly Quantumzyme Corp.) has filed Amendment No. 1 to its Quarterly Report on Form 10-Q for the period ended October 31, 2025. This amendment is solely to update Item 2—Management’s Discussion and Analysis of Financial Conditions and Results of Operations—with additional disclosure regarding the company’s intellectual property and the formalization of certain rights previously acquired.

Financial Overview

• No Revenue Generation: The company reported no revenues for the three months ended October 31, 2025, compared to the same period in 2024. This is a critical point for investors as it underscores the company’s early-stage and pre-revenue status.
• Operating Expenses: Operating expenses for Q3 2025 totaled \$39,196, a decrease from the previous year’s \$60,934. The reduction was primarily due to lower professional fees.
• Other Expenses: Other expenses increased to \$10,672 in Q3 2025, from \$4,589 in Q3 2024, attributed to higher interest expenses from additional debt incurred.
• Net Loss: The company posted a net loss of \$49,868 for Q3 2025, an improvement from the \$65,523 net loss in Q3 2024. This improvement stems from reduced operating expenses.
• Accumulated Deficit: As of October 31, 2025, the accumulated deficit was \$5,686,435.
• Liquidity and Capital Resources: The company had total current assets of \$184 and total current liabilities of \$490,769, resulting in a working capital deficit of \$490,585.
• Cash Flow: Operations used \$19,913 in cash in Q3 2025 (versus \$35,057 in Q3 2024). Financing activities provided \$19,513 in cash, down from \$40,125 the prior year, reflecting fewer notes issued.

Going Concern Warning

The company’s financial statements have been prepared on a going concern basis, but with net losses, substantial accumulated deficits, and negative cash flows, substantial doubt exists about Quantum Genesis AI Corp.’s ability to continue as a going concern. The company is entirely dependent on its ability to raise funds through securities sales or external sources, and currently has no firm financing agreements. If the company cannot secure funding, it may need to suspend operations, which could result in significant losses for shareholders. Additional equity financing, if obtained, may cause substantial dilution.

Intellectual Property—Potentially Price Sensitive Update

Major news: The company’s intellectual property portfolio now includes proprietary enzyme design technologies and computational methodologies acquired through an Asset Purchase Agreement dated February 21, 2023. This includes the subject matter of U.S. Patent Application Publication No. US20250146029A1, titled “Modified Polypeptides for Enzymatic Synthesis of Ibuprofen“, filed November 2, 2023.

The patent application was filed in the name of the company’s Chief Executive Officer, Naveen Krishnarao Kulkarni. To clarify ownership and provide certainty for investors, Quantum Genesis AI Corp. and its CEO have executed an Assignment Agreement to formalize and document the transfer of all rights, title, and interest in this intellectual property to the company, effective as of November 2, 2023.

This clarification of IP ownership and patent rights could be price sensitive, as it strengthens the company’s asset base and addresses any ambiguity regarding the control of its core technology. Such developments are pivotal for future fundraising, partnerships, and commercialization potential.

Shareholder Information

• Shares Outstanding: 38,962,050 shares of common stock as of December 15, 2025.
• Emerging Growth Company: The company is classified as both a smaller reporting company and an emerging growth company, and has elected not to use extended transition periods for new accounting standards.
• Shell Company Status: The company is not considered a shell company.

Conclusion

Investors should note the following potentially price-sensitive items:

• Formalization and clarification of core intellectual property and patent rights
• Continued going concern warning—future funding is uncertain
• Zero revenue and ongoing net losses—business is still pre-commercial

The patent assignment and confirmation of IP ownership is a positive development that may impact share value, particularly if the technology is commercialized or attracts partners/investors. However, liquidity concerns and the warning regarding the company’s ability to continue as a going concern remain significant risks for shareholders.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. All forward-looking statements are subject to risks and uncertainties—actual results may differ materially from those expressed or implied. Quantum Genesis AI Corp. undertakes no obligation to update forward-looking statements.

View Quantum Genesis AI Corp. Historical chart here